Is it worthwhile delaying MTX start for a month in RA, to vaccinate effectively? VACIMRA (multicentre 🇫🇷) showed it marginally improves pneumococcal vaccine immunogenicity, persisting to 1y, no extra pred needed. I’ll admit, I’m still not game! #EULAR2024 OP0140 @RheumNow https://t.co/58qJxki8ov

• https://twitter.com/drdavidliew/status/1801179511561785657/photo/1
• https://twitter.com/drdavidliew/status/1801179511561785657/photo/1
• https://twitter.com/drdavidliew/status/1801179511561785657/photo/1
• https://twitter.com/drdavidliew/status/1801179511561785657/photo/1

OP0131 on occurrence & predictors of #DMARD treatment failure in #RA 8% of pts failed ≥3 b/tsDMARDs with ~4yrs to failure In pts starting first b/tsDMARD, up to 25% fail ≥2 b/tsDMARDs in 3yrs Risk of fulfilling EULAR D2T criterion 1 ➡️ 2.3% in first 5yrs @RheumNow #EULAR2024

#Vaccinations against #herpes #zoster in #MTX +#Upadacitinib Pts ▶️ #Shingrix works 👍Pts followed to 60 months #EULAR2024 @eular_org @RheumNow #OP0020 https://t.co/8ORC3Nd2FK

• https://twitter.com/drdavidliew/status/1800906791502647424

AMPLIFIED RCT, 300+ pts ABA NOT (!) superior to ADA in dual seropositive SE+ MTX IR RA pts ACR50 rate high in both gps ABA 59% vs ADA 64% No new safety signal Defeating the encouraging data from smaller trials Abstr#OP0007 #EULAR2024 @RheumNow https://t.co/PvRUnpthHl

• https://twitter.com/AurelieRheumo/status/1800938588101599607/photo/1

Shingrix in upadacitinib + MTX RA, in SELECT-COMPARE RCT: data now out to 60w good humoral and cellular response in most, even without MTX withheld (& good safety too) Important for our JAKi-treated patients to get the protection they need #EULAR2024 OP0020 @RheumNow https://t.co/FqVCCwUJOg

• https://twitter.com/drdavidliew/status/1800906791502647424/photo/1
• https://twitter.com/drdavidliew/status/1800906791502647424/photo/1

Significant proportion of patients in PsA do not achieve remission across the domains. This can be due to disease heterogeneity, domain differences, comorbidities. There is a need to study the use of combination ts and bDMARDs. Difficult to Manage PsA session #EULAR2024 Ribeiro,… https://t.co/Wt3jgtIR9N https://t.co/VzCApikqek

• https://twitter.com/i/web/status/1800870035440775350
• https://twitter.com/synovialjoints/status/1800870035440775350/photo/1
• https://twitter.com/synovialjoints/status/1800870035440775350/photo/1

Grappa difficult to treat PsA meeting - SLR, Patient & rheumo survey, definition eg - fail 1 csDMARD & 2 bDMARDs different MOA - names matter suggest ditch « difficult » for « refractory » @rheumnow #EULAR2024